Wolters Kluwer Adds Drug Class Monographs and Other Enhancements to Lexicomp Online Drug Reference

Date: 
Thursday, October 20, 2016

October 20, 2016 – The Health division of Wolters Kluwer, a leading global provider of information and point of care solutions for the healthcare industry, is once again enhancing its Lexicomp® drug information reference solutions with new content and features. All enhancements are intended to make Lexicomp Online and Lexicomp Mobile Apps more efficient and add to the wealth of information and tools healthcare professionals trust to support their medication decisions and help them reduce errors.

Chief among the recent enhancements is the addition of drug class monographs. Available to subscribers to the Formulary Decision Support Bundle of additional, specialized tools, drug class monographs feature details about drug properties common to given pharmacologic classes to assist professionals with drug therapy decisions. Links to class monographs have been added to more than 550 monographs in the Lexicomp core drug information database.

Other recent enhancements include:

  • In-line referencing added to "Uses: Off-label" field in core drug monographs
  • New drug pricing field in pediatric and neonatal drug monographs to improve workflow efficiency
  • Multinational drugs added to Toxicology module to support a more global view of medication safety
  • Addition of Brazilian and International Nonproprietary Names to architecture to support more effective searching in languages other than English

"Lexicomp Online is renowned for providing clear, concise, relevant drug information to help professionals make safe, well-informed medication decisions," said Denise Basow, MD, President & CEO of Clinical Effectiveness at Wolters Kluwer. "With easy, one-click access to drug class monographs, as well as new monograph fields and better support for clinicians practicing global medicine, Lexicomp is an even stronger resource for professionals dedicated to improving medication safety and reducing costly and harmful drug adverse events."

About Wolters Kluwer

Wolters Kluwer N.V. (AEX:WKL) is a global leader in information services and solutions for professionals in the health, tax and accounting, risk and compliance, finance and legal sectors. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with specialized technology and services.

Wolters Kluwer reported 2015 annual revenues of €4.2 billion. The company, headquartered in Alphen aan den Rijn, the Netherlands, serves customers in over 180 countries, maintains operations in over 40 countries and employs 19,000 people worldwide.

Wolters Kluwer shares are listed on Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices. Wolters Kluwer has a sponsored Level 1 American Depositary Receipt program. The ADRs are traded on the over-the-counter market in the U.S. (WTKWY).

Wolters Kluwer Health is a leading global provider of information and point of care solutions for the healthcare industry. For more information about our products and organization, visit http://www.wolterskluwer.com/, follow @WKHealth or @Wolters_Kluwer on Twitter, like us on Facebook, follow us on LinkedIn, or follow WoltersKluwerComms on YouTube.

Contacts

Media
Wolters Kluwer | Clinical Effectiveness
Meagan McCord, 330-650-6506
Manager, Marketing Communications, Clinical Drug Information
meagan.mccord@wolterskluwer.com